SOUTHBOROUGH, Mass.– Clinical research organization Veristat has extended its congratulations to George Medicines following the U.S. Food and Drug Administration (FDA) approval of WIDAPLIK™, a novel single-pill combination therapy for adults with hypertension. The approval marks a significant step forward in the management of high blood pressure and expands treatment options for millions of patients.
WIDAPLIK™, which combines telmisartan, amlodipine, and indapamide, is approved for use as an initial treatment to lower blood pressure. It is the first therapy of its kind to combine these three agents into one pill, offering a potentially more effective and convenient option for patients.
Veristat played a key role in supporting George Medicines throughout the pivotal trial and regulatory approval process. The CRO provided critical statistical consulting, biometrics services, and strategic guidance during FDA interactions.
“We are thrilled to see WIDAPLIK™ receive FDA approval,” said Veristat CEO Patrick Flanagan. “This achievement reflects the strength of our collaboration with George Medicines and demonstrates our shared commitment to advancing innovative therapies for patients.”
Robin Bliss, PhD, Vice President of Strategic Consulting at Veristat, added that the approval illustrates how strong partnerships can accelerate scientific progress. “This is a meaningful milestone, not only for George Medicines and Veristat, but for the patients who now have access to a groundbreaking new option for managing hypertension,” she said.
George Medicines also acknowledged Veristat’s contributions during the development of WIDAPLIK™, emphasizing the importance of their partnership in achieving this regulatory success.
Veristat continues to support biopharmaceutical innovators in bringing new therapies to market, particularly those targeting unmet medical needs and chronic conditions such as hypertension.
